Welcome to the e-CCO Library!

search
Search by: 
Year: Category:
Oral Presentation: OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis
Year: 2019
Source: Scientific Programme
Authors: Laurent Peyrin-Biroulet
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP10: Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitis
Year: 2019
Source: Scientific Programme
Authors: Johanne Brooks
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP11: Organoids derived from inflamed intestinal biopsies of patients with ulcerative colitis lose their inflammatory phenotype during ex vivo culture
Year: 2019
Source: Scientific Programme
Authors: Kaline Arnauts
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP12: Targeting inflammation in ulcerative colitis by inhibiting glucose uptake
Year: 2019
Source: Scientific Programme
Authors: Roswitha Gropp
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP13: Molecular response to ustekinumab in moderate-to-severe ulcerative colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study
Year: 2019
Source: Scientific Programme
Authors: Katherine Li
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately-to-severely active ulcerative colitis: data from the U-ACHIEVE study
Year: 2019
Source: Scientific Programme
Authors: William J. Sandborn
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of mild to moderate ulcerative colitis: efficacy results
Year: 2019
Source: Scientific Programme
Authors: Stuart Bloom
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies
Year: 2019
Source: Scientific Programme
Authors: Mayte Suarez-Farinas
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in pediatric patients with Crohn’s disease: The pediatric Crohn's disease adalimumab level-based optimization treatment (PAILOT) trial
Year: 2019
Source: Scientific Programme
Authors: Amit Assa
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitis
Year: 2019
Source: Scientific Programme
Authors: Yael Haberman
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s Disease
Year: 2019
Source: Scientific Programme
Authors: Amy Lewis
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP21: ABX464 is safe and efficacious in a proof of concept study in ulcerative colitis patients
Year: 2019
Source: Scientific Programme
Authors: Jean-Marc Steens
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal models
Year: 2019
Source: Scientific Programme
Authors: Jieun Shin
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's disease
Year: 2019
Source: Scientific Programme
Authors: Mathurin Fumery
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease
Year: 2019
Source: Scientific Programme
Authors: Erwin Dreesen
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: Final results from the GEMINI LTS study
Year: 2019
Source: Scientific Programme
Authors: Remo Panaccione
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer
Year: 2019
Source: Scientific Programme
Authors: Loris Riccardo Lopetuso
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP30: Serum proteomic profiling predicts and diagnoses pouchitis in ulcerative colitis patients undergoing ileal pouch-anal anastomosis
Year: 2019
Source: Scientific Programme
Authors: Kathleen Machiels
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP34: VARSITY: A Double-Blind, Double-Dummy, Randomised, Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis
Year: 2019
Source: Scientific Programme
Authors: Stefan Schreiber
Created: Wednesday, 5 June 2019, 9:01 PM
Oral Presentation: OP37: Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI
Year: 2019
Source: Scientific Programme
Authors: William J. Sandborn
Created: Wednesday, 5 June 2019, 9:01 PM